This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Specifically, HCPs raised concerns over how pharmacy benefit managers (PBMs) and insurers inappropriately use utilization management tools, like prior authorization, to deny or delay care, ultimately harming the patient and impacting patient access to care.
Half of every dollar spent on medicines goes to entities that don’t make medicine—like pharmacy benefit managers (PBMs) and insurers who are aggressively consolidating their control over health care and hospitals, clinics and for-profit pharmacies in the 340B markup program.
Health insurance companies will still offer older adults a lot of plan choices with low, or completely free, premiums. However, insurers have made important but subtle tweaks to next year’s plans that will force millions of members to shell out more for their prescription drugs and overall medical care than they do currently.
Over the past few weeks, Medicare Advantage insurers demanded that the Biden administration give them higher payment rates for next year. The result: In 2025, right after a new president is elected, Medicare Advantage insurers will have to absorb a slight decrease of 0.2% Continue to STAT+ to read the full story…
For years, health insurers battled to gain market share in the lucrative privatized Medicare program. Some of the companies say they designed their 2025 plans with an eye toward ditching members. When insurers release their 2025 plan offerings on Oct. Now, the opposite is true.
Analyses of 2025 Medicare Advantage star ratings continue to pour in and not all of it bodes well for the conventional juggernauts. We break down how all major insurers—and their investors—are reacting. UnitedHealth and Humana saw star ratings decrease, whereas insurtechs celebrated their scores.
How much does pravastatin cost without insurance? Even with private insurance, a number of variables impact the out-of-pocket cost of the drug. Without insurance, the retail cost of pravastatin may still differ from one person to another. Most insurance companies do cover pravastatin. Related: What is pravastatin?
The public will soon find out whether the federal government is willing to meet the health insurance industry’s demands and deposit more money into the bank accounts of next year’s Medicare Advantage plans.
Health insurer Centene will not pay any commissions to brokers and agents who help people sign up for next year’s Medicare prescription drug plans. “We have made a difficult decision — effective Jan. million enrollees.
AUSTIN, Texas—The second annual Fierce Health Payer Summit kicked off Wednesday to tackle the most pressing issues facing health plan leaders. AUSTIN, Texas—On Day 1 of the Fierce Health Payer Summit, panelists discussed the role of technology to retain members, trends in Medicare Advantage and changes to Medicare Part D.
The insurer will receive a recalculated score from the federal agency, potentially giving the insurer more in quality bonus payments. UnitedHealthcare successfully won its lawsuit over the Centers for Medicare and Medicaid Services, a federal judge determined Nov.
The federal government is rescoring the quality ratings of this year’s Medicare Advantage plans, which could lead to an additional $1 billion of taxpayer money flowing into the coffers of health insurance companies. The Wall Street Journal reported earlier about the government’s pending action.
The Centers for Medicare & Medicaid Services (CMS) is discontinuing the Medicare Advantage (MA) Value-Based Insurance Design model at the end of 2025. | The Value-Based Insurance Design model for Medicare Advantage plans will be terminated at the end of next year.
Insurers will feel resentful Monday as the feds opted to not reverse its decision to decrease Medicare Advantage benchmark payments by 0.16%, the Centers for Medicare and Medicaid announced. | Benchmark payments will still decrease 0.16% but the feds expect it will still pay up to $600 billion in payments to plans in 2025.
Blue Cross and Blue Shield of Kansas City is leaving the Medicare Advantage (MA) market at the end of 2024, the insurer announced recently. Blue Cross and Blue Shield of Kansas City is opting out of the Medicare Advantage market.
But they could severely warp the economics of local markets for patients, employers, and insurers — and Lina Khan’s Federal Trade Commission is eager to make Big Physician a lot smaller. Read the rest…
The California Public Employees’ Retirement System is making a drastic change to one of its major health insurance plans for the state’s employees and retirees: It’s switching health insurance carriers, and forcing its new partners to earn their fees instead of automatically getting them.
Beginning in 2025, health plans sold in state-run insurance exchanges would be required to meet time and distance standards that are at least as adequate as mandated on federal marketplaces, accord | State insurance exchanges would be required to meet the same standards as federal exchanges under a new rule by CMS on Wednesday.
CVS Health is preparing to make significant changes to its 2025 Medicare Advantage plans, which could potentially drive away 10% of its membership, the company’s chief financial officer said at an investment banking conference Tuesday. That’s entirely possible. million enrollees as of April, according to the latest federal data.
UnitedHealth Group is suing the Centers for Medicare and Medicaid Services, asking a judge to halt the federal agency from lowering the insurance company’s 2025 Medicare Advantage quality ratings.
The insurer missed its quarterly earnings target and previewed its 2025 guidance. Molina Healthcare CEO Joe Zubretsky predicted future Medicaid reform in Congress will be minimal.
On March 4, 2025, the U.S. Anticoagulants are some of the most commonly prescribed medications in the United States, and Xarelto is an expensive prescription with an average cost of over $600 for a monthly supply without insurance. The approval is for the 2.5 This approval should help reduce the prices of this essential medication.
The cost of semaglutide can vary on whether youre getting a brand-name or compounded version and whether you have insurance coverage. A monthly supply of semaglutide ranges from about $129$1,850 without insurance. Is semaglutide covered by insurance? Does insurance cover Ozempic? Does insurance cover Wegovy?
The Medicare Advantage market is expected to grow in 2025, despite big changes from insurers , STAT reports. Health insurance companies will still offer older adults a lot of plan choices with low, or completely free, premiums.
Humana, the country’s second largest Medicare Advantage insurer, is aggressively culling its plan offerings after several quarters of spending more than expected on its members’ medical care, and getting hammered on Wall Street for it.
What to make of the 2025 Medicare enrollment season In four weeks, Medicare beneficiaries will be able to sign up for 2025 coverage. CVS Health and Humana have been the most vocal major insurers about scaling back their Medicare Advantage plan offerings to improve profits.
billion in 2025, to a total of $88.2 Since 2021, hospitals have been required to post the prices they have negotiated with all health insurance companies, as well as their cash prices. The rule will increase spending in hospital outpatient departments by an estimated $5.2 Continue to STAT+ to read the full story…
The federal government is proposing to rein in health insurance companies that entice brokers with lavish bonuses to sell their Medicare Advantage plans by placing a firmer cap on broker compensation.
Freespira CEO Joe Perekupka told STAT the company believes it will break even by the end of 2025 and will become cash flow positive in 2026. Perekupka said Freespira hopes to enroll 2,500 people in its treatment this year — twice last year’s sales — and to double its patients again in 2025 and 2026.
Deductibles are a set amount of money you must pay out-of-pocket for medication before your standard coverage or copays kick in, and this amount has increased over these past 18 years from $250 per year in 2006 to $590 per year in 2025. The second most significant change for 2025 is the out-of-pocket maximum.
WASHINGTON (AP) — President Biden on Friday rolled out a new set of initiatives to reduce health care costs: a crackdown on scam insurance plans, new guidance to prevent surprise medical bills and an effort to reduce medical debt tied to credit cards. Read the rest…
Without insurance, the cost of Xigduo XR varies by dosage, averaging about $390 per month, but there are ways to make it more affordable. A Xigduo XR generic version may become available in 2025 , when the brand-name patent is set to expire. Is Xigduo XR covered by insurance? How much does Xigduo XR cost without insurance?
Centene is taking the federal government to court over the scoring of next year’s star ratings, as the latest major insurer to cry foul over the results. Centene is joining the ranks of frustrated insurers who say misclassified secret shopper calls are causing profound financial damage that should be rectified.
The earliest a generic version may be available is 2025, but that’s not guaranteed. Is Incruse Ellipta covered by insurance? Some health insurance plans or Medicare drug plans cover Incruse Ellipta, but coverage varies by plan. Insurance plans tend to put Incruse Ellipta in their top drug tiers, so copay costs may be high.
Is Edarbyclor covered by insurance? | How much does Edarbyclor cost without insurance? | How to get Edarbyclor without insurance. The earliest that generic azilsartan could be on the market is 2025. Is Edarbyclor covered by insurance? Edarbyclor cost without insurance? SingleCare price. Savings options.
While Lumigan is a 0.01% solution of bimatoprost and no generic product is manufactured at this concentration, patents on Lumigan expire in 2025 and 2027, so there may be a generic option approved by the Food and Drug Administration (FDA) thereafter. Is Lumigan covered by insurance? How much does Lumigan cost without insurance?
Is Nexplanon covered by insurance? | How much does Nexplanon cost without insurance? | How to get Nexplanon without insurance Nexplanon is a brand-name prescription birth control implant that does not contain estrogen. in 2027 and other countries in 2025, when a generic version may be approved.
Is Namzaric covered by insurance? | How much does Namzaric cost without insurance? | How to get Namzaric without insurance. There are, however, several effective ways for those without insurance to get Namzaric treatment at considerable savings. Is Namzaric covered by insurance? What is the generic for Namzaric?
Is Vyzulta covered by insurance? | How much does Vyzulta cost without insurance? | How to get Vyzulta without insurance Vyzulta is a brand-name prescription eye drop medication that is approved by the Food and Drug Administration (FDA) to reduce eye pressure in people with open-angle glaucoma or high eye pressure.
PBM headaches will still be around in 2025. Let’s talk about how to make 2025 the year you rise above PBM headaches and take back control of your pharmacy. Encourage Patients to Use Their Voice: Ask patients to share their insurance struggles with local lawmakers. Get your guide to making them just a wee bit better.
Due to its popularity, some people may wonder whether it’s covered by their health insurance plans, including Medicare. Without help from your health insurance plan, Medicare Part D, or Medicaid, you can expect to pay the typical retail price of $1,476 for a 28-day supply (a pack of four pens). How much does Mounjaro cost?
A new report explains the flow of dollars through the pharmaceutical supply chain for commercially insured patients taking retail medicines and details how transactions between stakeholders affect patient costs at the pharmacy counter.
It’s typically covered under commercial health insurance plans as well as Medicare and Medicaid. On top of that, Part D is undergoing changes in 2025 that will reduce drug costs for Medicare users, so that will also affect your costs moving forward. Depending on your choice of pharmacy, you may be able to pay $1,298 for 30, 1.5
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content